Gilead submits NDA for Quad Tablet
Following approval, the Quad will be the only once-daily, single-tablet regimen containing an integrase inhibitor. The submission of NDA was done on the back of positive data from
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.
The pharmacy automation solution is said to optimize medication ordering, dispensing, administration, charge capture, and inventory management processes. In addition, the medical center is also using McKesson’s ROBOT-Rx